OSR (NASDAQ:OSRH) Stock Price Down 25.1% – Here’s What Happened

OSR Holdings, Inc. (NASDAQ:OSRH)’s share price fell 25.1% during trading on Wednesday . The stock traded as low as $0.2507 and last traded at $0.2890. Approximately 2,807,246 shares traded hands during trading, an increase of 329% from the average session volume of 654,724 shares. The stock had previously closed at $0.3860.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on OSRH shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OSR in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

OSR Stock Down 25.1%

The firm’s 50-day simple moving average is $0.39 and its 200 day simple moving average is $0.48. The stock has a market capitalization of $10.15 million, a P/E ratio of -0.88 and a beta of 0.56.

OSR (NASDAQ:OSRH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.48 million for the quarter. OSR had a negative net margin of 363.26% and a negative return on equity of 7.24%.

Institutional Trading of OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP purchased a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned approximately 0.37% of OSR as of its most recent filing with the Securities and Exchange Commission (SEC). 55.30% of the stock is owned by institutional investors and hedge funds.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.